China News Service, June 5th. A report published on the website of the British "Nature" magazine on the 4th said that recently, China's Kexing new crown vaccine was included in the WHO emergency use list, which is "critical to curbing the global new crown pneumonia epidemic. Important", which will help promote vaccine distribution in low-income countries.

The picture shows on January 6, 2021, in the warehouse of Beijing Kexing Zhongwei Biotechnology Co., Ltd., located in Daxing District, Beijing, a staff member displays a cillin bottle of inactivated COVID-19 vaccine.

(Data Picture) Photo by Hou Yu, a reporter from China News Agency

  According to reports, on June 1st, the new inactivated vaccine "Kierlafor" developed by China Beijing Kexing Zhongwei Biotechnology Co., Ltd. was included in the WHO emergency use list.

The data shows that the effective rate of Kexing vaccine in preventing the appearance of new coronary symptoms is 51%, and the effective rate of preventing severe new coronary disease and hospitalization is as high as 100%.

  "Nature" magazine quoted Murat Akova, a clinical researcher of infectious diseases at the University of Hatchetpe in Turkey, as saying that Koxing vaccine, as a safe and effective new crown vaccine, "will make a major contribution to the global fight against the new crown epidemic." .

  The report pointed out that Kexing vaccine is also the second Chinese new crown vaccine included in the WHO emergency use list after the Sinopharm vaccine.

"These two Chinese vaccines have been widely used worldwide and are promoting China's large-scale vaccination campaign."

On the morning of March 29th, local time, Philippine Airlines flight PR361 was loading the first batch of Coxing vaccines purchased from China by the Philippine government, which is highly concerned by the entire Philippines.

Photo courtesy of Philippine Airlines issued by China News Service

  According to the report, worldwide, the cumulative supply of Coxing vaccine exceeds 600 million doses, and it is continuing to carry out vaccination activities in more than 40 countries and regions including Chile and Botswana.

Today, the emergency approval of the World Health Organization allows these two vaccines to be further distributed to low-income countries through the "New Coronary Vaccine Implementation Plan" (COVAX).

  A spokesperson for the Global Alliance for Vaccines and Immunization (GAVI) said, “GAVI welcomes the news that Kexing Vaccine has been included in the WHO’s emergency use list, because it means that the world has another safe and effective tool to combat this time. epidemic."

  The article mentioned that a trial conducted in the Brazilian town of Serana showed that the Coxing vaccine can play a major role in the fight against the epidemic.

There, 75% of adults have been vaccinated with two doses of Koxing vaccine, and the number of confirmed, hospitalized and death cases in the local area has been significantly reduced.

  Ricardo Palacios, the researcher in charge of the trial at the Butantin Institute, mentioned that although nearly 40% of the population commutes to the epidemic-ravaged area every day, the Coxing vaccine can protect entire towns. This fact is precisely the fact that "Significant evidence" that Kexing vaccine can "change the rules of the game in controlling the epidemic." (Finish)